Edition:
United States

Regeneron Pharmaceuticals Inc (REGN.OQ)

REGN.OQ on NASDAQ Stock Exchange Global Select Market

331.97USD
22 Jun 2018
Change (% chg)

$2.93 (+0.89%)
Prev Close
$329.04
Open
$330.05
Day's High
$334.52
Day's Low
$326.90
Volume
288,282
Avg. Vol
323,673
52-wk High
$543.50
52-wk Low
$281.89

Chart for

About

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have... (more)

Overall

Beta: 1.40
Market Cap(Mil.): $35,172.16
Shares Outstanding(Mil.): 105.95
Dividend: --
Yield (%): --

Financials

  REGN.OQ Industry Sector
P/E (TTM): 21.94 248.83 34.14
EPS (TTM): 15.13 -- --
ROI: 24.00 -5.25 13.10
ROE: 30.68 -6.83 15.09

Sanofi says on track to regain solid position in cancer drugs

PARIS Sanofi believes it can make a comeback and re-establish a leading position in the competitive cancer drug market on the back of its immunotherapy drugs and efforts in new areas such as molecular oncology.

Jun 13 2018

UPDATE 1-Sanofi says on track to regain solid position in cancer drugs

PARIS, June 13 Sanofi believes it can make a comeback and re-establish a leading position in the competitive cancer drug market on the back of its immunotherapy drugs and efforts in new areas such as molecular oncology.

Jun 13 2018

Regeneron's newer drugs disappoint, shares slip

Regeneron Pharmaceuticals Inc disappointed Wall Street with lower-than-expected sales of its newer treatments, eczema medicine Dupixent and heart drug Praluent, exacerbating concerns over the company's future sales growth as its best-selling eye drug Eylea faces more competition.

May 03 2018

UPDATE 3-Regeneron's newer drugs disappoint, shares slip

* Shares down 2 pct (Adds background, comments from conf. call and analyst, updates shares)

May 03 2018

BRIEF-Regeneron Reports Q1 GAAP Earnings Per Share $4.16

* REGENERON REPORTS FIRST QUARTER 2018 FINANCIAL AND OPERATING RESULTS

May 03 2018

Regeneron's first quarter profit soars 92 percent

May 3 Regeneron Pharmaceuticals Inc on Thursday posted a 92 percent rise in quarterly profit, as demand for its flagship eye treatment Eylea and eczema drug Dupixent increased.

May 03 2018

Regeneron/Sanofi cut heart drug price to $4,500-$6,600 for Express Scripts

Regeneron Pharmaceuticals Inc and Sanofi SA will slash the price of their expensive cholesterol drug for Express Scripts Holdings Co customers in exchange for greater patient access, with some savings to be shared with consumers, the companies said on Tuesday.

May 01 2018

BRIEF-Regeneron And Sanofi To Lower Net Price Of Praluent For Express Scripts Patients

* REGENERON AND SANOFI TO LOWER NET PRICE OF PRALUENT® (ALIROCUMAB) INJECTION IN EXCHANGE FOR STRAIGHTFORWARD, MORE AFFORDABLE PATIENT ACCESS FOR EXPRESS SCRIPTS PATIENTS

May 01 2018

Sanofi/Regeneron cut Praluent drug price in Express Scripts deal

May 1 Sanofi and Regeneron Pharmaceuticals said on Tuesday they had agreed to cut the price of their potent cholesterol drug, Praluent, under a deal with Express Scripts, the largest U.S. manager of prescription benefits.

May 01 2018

Regeneron/Sanofi to cut price of heart drug in Express Scripts deal

May 1 Regeneron Pharmaceuticals and Sanofi will cut the net price of their expensive cholesterol drug for Express Scripts customers in exchange for greater patient access, with some savings to be shared with consumers, the companies said on Tuesday.

May 01 2018

Competitors

  Price Chg
Novartis AG (NOVN.S) CHF75.60 +0.10
Pfizer Inc. (PFE.N) $36.51 +0.21
Bayer AG (BAYGn.DE) €98.84 +2.45
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €69.01 +1.30
Merck & Co., Inc. (MRK.N) $61.47 +0.29
Amgen, Inc. (AMGN.OQ) $185.15 -0.84
Roche Holding Ltd. (ROG.S) CHF216.45 --
Roche Holding Ltd. (RO.S) CHF223.60 +4.00
Eli Lilly And Co (LLY.N) $85.92 -0.15

Earnings vs. Estimates